title: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
abstract: Oxaliplatin is a platinum salt that is particularly effective in treating gastrointestinal tumours. Its increased use has resulted in emergence of allergic reactions, including anaphylactic shock. Allergic reactions to oxaliplatin documented over the last 5 years have been analysed using predefined criteria. The 42 analysed patients had cancer and received a FOLFOX regimen in first line or beyond. Two types of allergy were observed: a type I immediate allergic reaction in 39 patients in whom the most frequent signs were respiratory (50%) and cutaneous (40%); anaphylactic shock that occurred in three patients; type II allergy (immunological thrombopenia) was observed in three patients. All the toxicities were reversible on symptomatic treatment. No predictive factor was evidenced. Anaphylactic shock, is rare but serious, and must be considered in the event of any severe blood pressure decrease. For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence.
authors.affiliation: Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France. frederique.maindrault@sat.aphp.fr
authors.forename: Frédérique
authors.initials: F
authors.lastname: Maindrault-Goebel
authors.forename: Thierry
authors.initials: T
authors.lastname: André
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
authors.forename: Christophe
authors.initials: C
authors.lastname: Louvet
authors.forename: Nathalie
authors.initials: N
authors.lastname: Perez-Staub
authors.forename: Nora
authors.initials: N
authors.lastname: Zeghib
authors.forename: Aimery
authors.initials: A
authors.lastname: De Gramont
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced*; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil